MA28083A1 - Methodes de traitement de l'endometriose - Google Patents

Methodes de traitement de l'endometriose

Info

Publication number
MA28083A1
MA28083A1 MA28910A MA28910A MA28083A1 MA 28083 A1 MA28083 A1 MA 28083A1 MA 28910 A MA28910 A MA 28910A MA 28910 A MA28910 A MA 28910A MA 28083 A1 MA28083 A1 MA 28083A1
Authority
MA
Morocco
Prior art keywords
endometriosis
methods
treating endometriosis
nodules
adenomyomas
Prior art date
Application number
MA28910A
Other languages
English (en)
Inventor
Mirudhubashini Bovindarajan
Original Assignee
Miscon Trading S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miscon Trading S A filed Critical Miscon Trading S A
Publication of MA28083A1 publication Critical patent/MA28083A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Surgical Instruments (AREA)

Abstract

On peut traiter efficacement l'endométriose, y compris l'endométriose externe, les endométriomes, l'adénomyose, les adénomyomes, les nodules adénomyotiques des ligaments utéro-sacrés, et les nodules endométriotiques, tels que l'endométriose sur cicatrice, par administration intralésionnelle, y compris transvaginale, endoscopique ou par une chirurgie ouverte, y compris la laparotomie, d'un progestogène. L'invention concerne également des compositions utilisées à cet effet.
MA28910A 2003-09-03 2006-04-03 Methodes de traitement de l'endometriose MA28083A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50021703P 2003-09-03 2003-09-03
US52635503P 2003-12-01 2003-12-01

Publications (1)

Publication Number Publication Date
MA28083A1 true MA28083A1 (fr) 2006-08-01

Family

ID=34278698

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28910A MA28083A1 (fr) 2003-09-03 2006-04-03 Methodes de traitement de l'endometriose

Country Status (21)

Country Link
US (2) US9532995B2 (fr)
EP (2) EP2617411A1 (fr)
JP (2) JP5651279B2 (fr)
KR (2) KR101288265B1 (fr)
CN (1) CN101849906A (fr)
AU (1) AU2004267956B2 (fr)
BR (1) BRPI0413200A (fr)
CA (1) CA2537702C (fr)
DK (1) DK1660009T3 (fr)
EA (1) EA015356B1 (fr)
ES (1) ES2535430T3 (fr)
HR (1) HRP20150440T1 (fr)
HU (1) HUE025239T2 (fr)
IL (1) IL174014A0 (fr)
MA (1) MA28083A1 (fr)
NO (1) NO20061502L (fr)
PL (1) PL1660009T3 (fr)
PT (1) PT1660009E (fr)
SI (1) SI1660009T1 (fr)
TN (1) TNSN06070A1 (fr)
WO (1) WO2005020880A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
WO2009140126A1 (fr) * 2008-05-14 2009-11-19 Juneau Biosciences, Llc Procédé d’administration d’un agent thérapeutique
WO2010124101A2 (fr) 2009-04-22 2010-10-28 Juneau Biosciences, Llc Marqueurs génétiques associés à l'endométriose et utilisation de ceux-ci
EP2632346A4 (fr) * 2010-01-05 2015-05-27 Beacon Endoscopic Corp Méthodes et appareil pour anastomose par compression induite magnétiquement entre des organes adjacents
EP2471537A1 (fr) * 2010-12-30 2012-07-04 PregLem S.A. Traitement de la douleur associé à la dislocation de l'endomètre de base
AR082266A1 (es) * 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3068223B1 (fr) * 2013-11-12 2020-01-01 University of Utah Research Foundation Hydrogel thermosensible à base de glycol-chitine pour administration de progestérone par voie vaginale
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3518943A4 (fr) * 2016-09-28 2020-04-22 Atossa Therapeutics, Inc. Méthodes de thérapie cellulaire adoptive
RU2661701C1 (ru) * 2017-02-09 2018-07-19 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ лапароскопического лечения узловых форм аденомиоза
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN115605187B (zh) * 2020-02-26 2024-09-17 福多兹制药公司 载有孕激素药物的可注射控释制剂
RU2746476C1 (ru) * 2020-04-28 2021-04-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ хирургического лечения глубокого инфильтративного эндометриоза ректовагинальной перегородки
GB2594726A (en) * 2020-05-05 2021-11-10 Nadezhda Reproductive Science Ood Adenomyosis associated infertility and HDACIs
WO2026015620A1 (fr) 2024-07-09 2026-01-15 Farmastar Llc Formulations pharmaceutiques stables de progestogènes

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543A (en) 1848-05-02 of jbesey city
US12703A (en) * 1855-04-10 Gabhst-chaie
US4038A (en) 1845-05-10 Boot-crimp
US5362A (en) 1847-11-06 Ice-ctjttee
US150A (en) 1837-03-25 Island
US61303A (en) * 1867-01-15 James yocom
US720A (en) 1838-04-28 Improved mode of forming a kiln for making charcoal
US389A (en) 1837-09-21 Mode of supporting the bodies of railroad-cars and carriages
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
GB784659A (en) 1954-11-26 1957-10-16 Upjohn Co Therapeutic compositions and aqueous suspensions thereof
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
GB2252497B (en) 1991-02-04 1995-01-18 Elsimar Metzker Coutinho Pharmaceutical composition
JPH0735335B2 (ja) 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
RU2073534C1 (ru) 1993-06-04 1997-02-20 Сочинский научно-исследовательский институт курортологии и физиотерапии МЗ РФ Способ лечения генитального эндометриоза
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
EP1488794A3 (fr) * 1994-11-22 2005-04-20 Balance Pharmaceuticals, Inc. Méthodes de contraception
EP0785212A1 (fr) 1996-01-22 1997-07-23 Laboratoire Theramex Nouveaux dérivés de 19-nor-pregnane
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
CA2344316A1 (fr) 1998-09-16 2000-03-23 Saira Sayed Singh Traitement des tumeurs oncologiques par formulation injectable a base d'agent perturbateur pour appareil de golgi
WO2000021511A2 (fr) 1998-10-09 2000-04-20 Pharmacia & Upjohn Company Acetate de medroxyprogesterone administre par voie sous-cutanee en vue du traitement de la menopause et de l'endometriose
JP2001051773A (ja) * 1999-08-16 2001-02-23 Toshiaki Matsuhashi キーボードカバー
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20030165568A1 (en) * 2000-05-15 2003-09-04 Giuseppe Colombo Stabilized steroidal suspension
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
ATE427760T1 (de) * 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
JP4273208B2 (ja) * 2001-03-30 2009-06-03 チッソ株式会社 婦人科疾患治療剤
US20040105889A1 (en) 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms

Also Published As

Publication number Publication date
JP5651279B2 (ja) 2015-01-07
ES2535430T3 (es) 2015-05-11
WO2005020880A2 (fr) 2005-03-10
US9532995B2 (en) 2017-01-03
WO2005020880A3 (fr) 2006-05-26
BRPI0413200A (pt) 2006-10-03
KR20070017946A (ko) 2007-02-13
KR101285137B1 (ko) 2013-07-11
PL1660009T3 (pl) 2015-08-31
EP1660009A2 (fr) 2006-05-31
US20150044291A1 (en) 2015-02-12
JP2013035866A (ja) 2013-02-21
JP2007509032A (ja) 2007-04-12
EA015356B1 (ru) 2011-06-30
CA2537702C (fr) 2012-01-03
DK1660009T3 (en) 2015-04-27
EA200600524A1 (ru) 2006-08-25
KR101288265B1 (ko) 2013-07-26
NO20061502L (no) 2006-06-02
EP2617411A1 (fr) 2013-07-24
EP1660009A4 (fr) 2010-02-17
EP1660009B1 (fr) 2015-01-28
CA2537702A1 (fr) 2005-03-10
US9468647B2 (en) 2016-10-18
PT1660009E (pt) 2015-05-18
KR20120005062A (ko) 2012-01-13
CN101849906A (zh) 2010-10-06
AU2004267956B2 (en) 2010-09-16
AU2004267956A1 (en) 2005-03-10
HUE025239T2 (en) 2016-03-29
TNSN06070A1 (en) 2007-10-03
IL174014A0 (en) 2006-08-01
US20050085453A1 (en) 2005-04-21
HRP20150440T1 (hr) 2015-07-03
SI1660009T1 (sl) 2015-07-31
HK1095529A1 (zh) 2007-05-11

Similar Documents

Publication Publication Date Title
MA28083A1 (fr) Methodes de traitement de l'endometriose
BR0109189A (pt) Composições farmacêuticas de inibidores de fosforilase de glicogênio
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
CY1110742T1 (el) Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης
EP1641423A4 (fr) Antagonistes du recepteur du cgrp de
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
BRPI0410630A (pt) antagonista de nk1
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
NO20025450D0 (no) Ny farmasöytisk sammensetning
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
BR0212968A (pt) Composição farmacêutica, composto, e, método para tratar ou prevenir condições mediadas pelo ccr2, mcp-1 ou pela interação destes
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
BRPI0416489A (pt) polìmero superabsorvente tendo absorção de água livre atrasada
BR0108514A (pt) Uso de inibidores de il-18
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
BR0211604A (pt) Inibidores de integrina para o tratamento de doenças do olho
BR0214810A (pt) Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BRPI0409690A (pt) associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase
BRPI0409473A (pt) combinação de um inibidor de cox-2 e um agente antineoplásico do tipo alquilante para o tratamento de neoplasia
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
ID25478A (id) Agonis 5-ht1f